You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

Properties

Applications

Our Abpromise guarantee covers the use of ab11906 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
EMSA EMSA: Use at an assay dependent dilution.

Target

  • FunctionTranscription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters (By similarity). Inhibits MYST4-dependent transcriptional activation.
  • Tissue specificitySpecifically expressed in osteoblasts.
  • Involvement in diseaseDefects in RUNX2 are the cause of cleidocranial dysplasia (CLCD) [MIM:119600]; also known as cleidocranial dysostosis (CCD). CLCD is an autosomal dominant skeletal disorder with high penetrance and variable expressivity. It is due to defective endochondral and intramembranous bone formation. Typical features include hypoplasia/aplasia of clavicles, patent fontanelles, wormian bones (additional cranial plates caused by abnormal ossification of the calvaria), supernumerary teeth, short stature, and other skeletal changes. In some cases defects in RUNX2 are exclusively associated with dental anomalies.
  • Sequence similaritiesContains 1 Runt domain.
  • DomainA proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes and contains the phosphorylation sites.
  • Post-translational
    modifications
    Phosphorylated; probably by MAP kinases (MAPK) (By similarity). Isoform 3 is phosphorylated on Ser-340.
  • Cellular localizationNucleus.
  • Target information above from: UniProt accession Q13950 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
      Acute myeloid leukemia 3 protein antibodyalpha subunit 1 antibodyAML3 antibody
      CBF alpha 1 antibodyCBF-alpha-1 antibodyCBFA1 antibodyCCD antibodyCCD1 antibodycleidocranial dysplasia 1 antibodyCore binding factor antibodyCore binding factor runt domain alpha subunit 1 antibodyCore binding factor subunit alpha 1 antibodycore-binding factor antibodyCore-binding factor subunit alpha-1 antibodyMGC120022 antibodyMGC120023 antibodyOncogene AML 3 antibodyOncogene AML-3 antibodyOSF 2 antibodyOSF-2 antibodyOSF2 antibodyOsteoblast specific transcription factor 2 antibodyOsteoblast-specific transcription factor 2 antibodyOTTHUMP00000016533 antibodyPEA2 alpha A antibodyPEA2-alpha A antibodyPEA2aA antibodyPEBP2 alpha A antibodyPEBP2-alpha A antibodyPEBP2A1 antibodyPEBP2A2 antibodyPEBP2aA antibodyPEBP2aA antibodyPEBP2aA1 antibodyPolyomavirus enhancer binding protein 2 alpha A subunit antibodyPolyomavirus enhancer-binding protein 2 alpha A subunit antibodyrunt domain antibodyRunt related transcription factor 2 antibodyrunt-related transcription factor 2 antibodyRUNX2 antibodyRUNX2_HUMAN antibodySL3 3 enhancer factor 1 alpha A subunit antibodySL3-3 enhancer factor 1 alpha A subunit antibodySL3/AKV core binding factor alpha A subunit antibodySL3/AKV core-binding factor alpha A subunit antibody
    see all

Anti-RUNX2 antibody images

  • Nushift polyclonal antibody against AML3 factor creates a supershift in EMSA (lane 4).

References for Anti-RUNX2 antibody (ab11906)

This product has been referenced in:
  • Meyer KB  et al. Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer. PLoS Biol 6:e108 (2008). EMSA ; Human . Read more (PubMed: 18462018) »
  • Wang X  et al. p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix. Endocrinology 148:1629-37 (2007). WB ; Mouse . Read more (PubMed: 17185377) »

See all 3 Publications for this product

Product Wall

Displaying 1 - 6 of 6 results for Abreviews and Q&A

Thank you for sending along your EMSA data. Here are some ideas for potential controls you may consider to clarify the issue: 1) Do you have a control oligo (scrambled) or other labeled oligo to run in the EMSA to determine if ab11906 will bind oth...

Read More
Application Western blot
Sample Mouse Cell lysate - whole cell (MC3T3 mouse embryo/fetus calvaria fibroblasts)
Loading amount 50 µg
Specification MC3T3 mouse embryo/fetus calvaria fibroblasts
Gel Running Conditions Reduced Denaturing (PAGE 10%)
Blocking step Milk as blocking agent for 3 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
Username

Verified customer

Submitted May 09 2008

Application Western blot
Sample Rat Cell lysate - whole cell (osteoblasts UMR-108)
Loading amount 30 µg
Specification osteoblasts UMR-108
Blocking step Other as blocking agent for 16 hour(s) and 0 minute(s) · Concentration: zymed
Username

Verified customer

Submitted Jun 07 2006

We usually used 1 to 5 ug of extract in gelshift assays. Oligos used are: wt: 5' CCCGTAT TAA CCA CA AT AAA ACT CG 3' mut: 5' CCC GTA T TAA TGG CA AT AAA ACT CG 3' These oligos are double stranded but I only put here the forward strand in each ...

Read More

Thank you for your enquiry and I'm sorry to hear that you are experiencing difficulty with this antibody. Below is the protocol from the antibody's originator and they used 2-6 ul of antibody/reaction mixture. There have not been any other complaints...

Read More

Thank you for your recent phone call, as discussed on the phone I would recommend running a positive control of nuclear extract of Saos-2 cells and to use more antibody per IP/ChIP (e.g 40-5ul per 500ug lysate/10ug chromatin ) as this antibody is not puri...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"